STOCK TITAN

[25-NSE] CARGO Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
25-NSE

CARGO Therapeutics, Inc. (CRGX) submitted a Form 25 notification to remove a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer and exchange and references the Exchange and Issuer compliance provisions under 17 CFR 240.12d2-2(b)/(c). The document does not include a completed signature block, a specific rule box marked to indicate the basis for removal, a removal date, or any explanation of the reason for delisting.

CARGO Therapeutics, Inc. (CRGX) ha presentato una notifica Form 25 per rimuovere una classe dei suoi titoli dalla quotazione e/o registrazione sul Nasdaq Stock Market LLC. Il documento indica l'emittente e la borsa e fa riferimento alle disposizioni di conformità dell'Exchange e dell'Issuer ai sensi del 17 CFR 240.12d2-2(b)/(c). Il modulo non contiene un blocco firme completato, non indica una casella di regola specifica per motivare la rimozione, non riporta una data di rimozione né fornisce alcuna spiegazione sulle ragioni della delisting.

CARGO Therapeutics, Inc. (CRGX) presentó una notificación Form 25 para retirar una clase de sus valores de la cotización y/o registro en el Nasdaq Stock Market LLC. la presentación identifica al emisor y a la bolsa y hace referencia a las disposiciones de cumplimiento del Exchange y del Issuer conforme a 17 CFR 240.12d2-2(b)/(c). El documento no incluye un bloque de firma completado, no marca ninguna casilla de norma específica para indicar la base de la retirada, no especifica fecha de retirada ni aporta explicación sobre el motivo de la exclusión.

CARGO Therapeutics, Inc. (CRGX)는 Nasdaq Stock Market LLC에서 자사 증권의 한 종(class)을 상장 및/또는 등록 해제하기 위한 Form 25 통지를 제출했습니다. 서류에는 발행회사와 거래소가 명시되어 있으며 17 CFR 240.12d2-2(b)/(c)에 따른 거래소 및 발행인 준수 조항을 참조하고 있습니다. 해당 문서에는 작성된 서명란이 없고, 상장폐지 사유를 표시하는 특정 규정란이 체크되어 있지 않으며, 삭제일이나 상장폐지 사유에 대한 설명도 포함되어 있지 않습니다.

CARGO Therapeutics, Inc. (CRGX) a soumis une notification Form 25 visant à retirer une catégorie de ses titres de la cotation et/ou de l'enregistrement sur le Nasdaq Stock Market LLC. Le dossier identifie l'émetteur et la bourse et renvoie aux dispositions de conformité de l'Exchange et de l'Issuer en vertu du 17 CFR 240.12d2-2(b)/(c). Le document ne comporte pas de bloc de signature complété, n'indique aucune case de règle spécifique justifiant le retrait, ne mentionne pas de date de retrait et n'apporte aucune explication sur la raison de la radiation.

CARGO Therapeutics, Inc. (CRGX) hat eine Form-25-Mitteilung eingereicht, um eine Klasse ihrer Wertpapiere von der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC zu entfernen. Die Einreichung nennt den Emittenten und die Börse und verweist auf die Compliance-Bestimmungen des Exchange und des Issuer gemäß 17 CFR 240.12d2-2(b)/(c). Das Dokument enthält keinen ausgefüllten Signaturblock, kein spezifisch markiertes Regelkästchen zur Begründung der Entfernung, kein Entferndatum und keine Erklärung zum Delisting-Grund.

Positive
  • None.
Negative
  • Form 25 indicates removal/withdrawal from Nasdaq listing/registration for CARGO Therapeutics, Inc.
  • Filing lacks key execution details: the signature block is empty and no date or authorized signatory is shown.
  • No specific rule box is marked to indicate the precise statutory provision used for the strike/withdrawal in the provided content.
  • No reason or effective date for the removal is provided in the submitted text, limiting investor clarity.

Insights

TL;DR: Form 25 filed indicating Nasdaq removal/withdrawal process, but key details and signatures are absent.

The filing is a formal notification that CARGO Therapeutics' securities are being removed from listing/registration on Nasdaq, citing the Exchange's compliance with 17 CFR 240.12d2-2(b) and the issuer's compliance with 17 CFR 240.12d2-2(c). The document lacks the actual marked rule provision, an execution signature, and a specific effective or filing date, which limits readers' ability to determine timing and legal basis for the removal. For investors and regulators, the absence of those elements reduces the filing's informational usefulness.

TL;DR: The notice signals delisting activity but omits material procedural details needed to assess impact.

The Form 25 indicates Nasdaq initiated or is processing removal from listing/registration for a class of securities of CARGO Therapeutics, with references to applicable Exchange and SEC rule provisions. However, no explanation for the delisting, no effective date, and no authorized signatory are provided in the text supplied, preventing assessment of governance implications or next steps for stakeholders. This limits stakeholders' ability to evaluate disclosure completeness and compliance timing.

CARGO Therapeutics, Inc. (CRGX) ha presentato una notifica Form 25 per rimuovere una classe dei suoi titoli dalla quotazione e/o registrazione sul Nasdaq Stock Market LLC. Il documento indica l'emittente e la borsa e fa riferimento alle disposizioni di conformità dell'Exchange e dell'Issuer ai sensi del 17 CFR 240.12d2-2(b)/(c). Il modulo non contiene un blocco firme completato, non indica una casella di regola specifica per motivare la rimozione, non riporta una data di rimozione né fornisce alcuna spiegazione sulle ragioni della delisting.

CARGO Therapeutics, Inc. (CRGX) presentó una notificación Form 25 para retirar una clase de sus valores de la cotización y/o registro en el Nasdaq Stock Market LLC. la presentación identifica al emisor y a la bolsa y hace referencia a las disposiciones de cumplimiento del Exchange y del Issuer conforme a 17 CFR 240.12d2-2(b)/(c). El documento no incluye un bloque de firma completado, no marca ninguna casilla de norma específica para indicar la base de la retirada, no especifica fecha de retirada ni aporta explicación sobre el motivo de la exclusión.

CARGO Therapeutics, Inc. (CRGX)는 Nasdaq Stock Market LLC에서 자사 증권의 한 종(class)을 상장 및/또는 등록 해제하기 위한 Form 25 통지를 제출했습니다. 서류에는 발행회사와 거래소가 명시되어 있으며 17 CFR 240.12d2-2(b)/(c)에 따른 거래소 및 발행인 준수 조항을 참조하고 있습니다. 해당 문서에는 작성된 서명란이 없고, 상장폐지 사유를 표시하는 특정 규정란이 체크되어 있지 않으며, 삭제일이나 상장폐지 사유에 대한 설명도 포함되어 있지 않습니다.

CARGO Therapeutics, Inc. (CRGX) a soumis une notification Form 25 visant à retirer une catégorie de ses titres de la cotation et/ou de l'enregistrement sur le Nasdaq Stock Market LLC. Le dossier identifie l'émetteur et la bourse et renvoie aux dispositions de conformité de l'Exchange et de l'Issuer en vertu du 17 CFR 240.12d2-2(b)/(c). Le document ne comporte pas de bloc de signature complété, n'indique aucune case de règle spécifique justifiant le retrait, ne mentionne pas de date de retrait et n'apporte aucune explication sur la raison de la radiation.

CARGO Therapeutics, Inc. (CRGX) hat eine Form-25-Mitteilung eingereicht, um eine Klasse ihrer Wertpapiere von der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC zu entfernen. Die Einreichung nennt den Emittenten und die Börse und verweist auf die Compliance-Bestimmungen des Exchange und des Issuer gemäß 17 CFR 240.12d2-2(b)/(c). Das Dokument enthält keinen ausgefüllten Signaturblock, kein spezifisch markiertes Regelkästchen zur Begründung der Entfernung, kein Entferndatum und keine Erklärung zum Delisting-Grund.

UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-41859
Issuer: CARGO Therapeutics, Inc.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 1900 Alameda De Las Pulgas
Suite 350
San Mateo CALIFORNIA 94403
Telephone number: (415) 317-4997
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2025-08-19 By Tara Petta AVP
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 for CARGO Therapeutics (CRGX) state?

The Form 25 notifies that a class of CARGO Therapeutics' securities is being removed from listing and/or registration on the Nasdaq Stock Market LLC and references compliance with 17 CFR 240.12d2-2(b) and 12d2-2(c).

Does the filing show why CRGX is being removed from Nasdaq?

No. The provided filing text does not include an explanation of the reason for removal.

Is there an effective date or signature on the Form 25 for CRGX?

No. The supplied content shows an empty signature/date block and does not state an effective removal date.

Which regulatory provisions are cited in the CRGX Form 25?

The filing references 17 CFR 240.12d2-2(b) and 17 CFR 240.12d2-2(c) and lists possible rule provisions under 17 CFR 240.12d2-2(a)(1)-(4).

Does this Form 25 confirm whether the removal is voluntary or mandatory?

The filing text does not specify. It references both Exchange compliance and issuer compliance provisions but does not clearly state whether the withdrawal is voluntary or initiated by the Exchange.
Cargo Therapeutics

NASDAQ:CRGX

CRGX Rankings

CRGX Latest News

CRGX Latest SEC Filings

CRGX Stock Data

216.19M
48.11M
0.63%
99.29%
6.53%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN CARLOS